Source:http://linkedlifedata.com/resource/pubmed/id/17654702
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2007-11-5
|
| pubmed:abstractText |
After hepatitis B e antigen (HBeAg) seroconversion, hepatitis B may become inactive or progress to HBeAg-negative hepatitis with persistent or intermittent alanine aminotransferase (ALT) elevation. The aim of this study was to prospectively identify factors predictive of the clinical course in HBeAg-negative chronic hepatitis B (CHB). Patients were stratified by ALT and HBeAg status and followed every 3 months for up to 5 years. Kaplan-Meier and Cox regression analysis using the change from normal ALT to elevated ALT as endpoints were performed to determine factors associated with ALT elevation/normalization. Seventy-four HBeAg-negative and 32 HBeAg-positive patients were prospectively evaluated. For HBeAg-negative patients, hepatitis B virus (HBV) DNA was predictive of future ALT. Only 1 patient with normal ALT and an HBV DNA value lower than 10,000 copies/mL developed an elevated ALT within the subsequent year, whereas 67% with an HBV DNA value greater than 100,000 copies/mL had a rise in ALT above normal within 1 year. Patients with a previous history of ALT elevation and longer follow-up at all levels of HBV DNA were more likely to experience ALT elevations. For HBeAg-negative patients with elevated ALT and all HBeAg-positive patients, HBV DNA did not predict future ALT. Other viral and host factors were not predictive of future ALT. CONCLUSION: HBeAg-negative CHB has a fluctuating course. HBV DNA values lower than 10,000 copies/mL predict persistently normal ALT for at least 1 year. Patients with HBV DNA values between 10,000 and 100,000 copies/mL can safely be followed at 6 monthly intervals, whereas HBV DNA values greater than 100,000 copies/mL are highly predictive of future ALT elevation and should prompt regular follow-up.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0270-9139
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
46
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1057-70
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:17654702-Adult,
pubmed-meshheading:17654702-Aged,
pubmed-meshheading:17654702-Alanine Transaminase,
pubmed-meshheading:17654702-Biopsy,
pubmed-meshheading:17654702-Cohort Studies,
pubmed-meshheading:17654702-DNA, Viral,
pubmed-meshheading:17654702-Disease Progression,
pubmed-meshheading:17654702-Female,
pubmed-meshheading:17654702-Follow-Up Studies,
pubmed-meshheading:17654702-Hepatitis B, Chronic,
pubmed-meshheading:17654702-Hepatitis B e Antigens,
pubmed-meshheading:17654702-Hepatitis B virus,
pubmed-meshheading:17654702-Humans,
pubmed-meshheading:17654702-Kaplan-Meier Estimate,
pubmed-meshheading:17654702-Liver,
pubmed-meshheading:17654702-Male,
pubmed-meshheading:17654702-Middle Aged,
pubmed-meshheading:17654702-Mutation,
pubmed-meshheading:17654702-Predictive Value of Tests,
pubmed-meshheading:17654702-Prognosis,
pubmed-meshheading:17654702-Proportional Hazards Models,
pubmed-meshheading:17654702-Prospective Studies
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B.
|
| pubmed:affiliation |
Department of Medicine, University of Toronto, Toronto, Canada. feldj@niddk.nih.gov
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't,
Evaluation Studies,
Research Support, N.I.H., Intramural
|